Understanding how a specific protein affects heart receptor function
Official title: Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinase
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10983325 · Data updated 2026-11-12
This study is looking at how a specific protein affects heart receptors that help control heart function, with the goal of finding new ways to improve heart health for people dealing with heart failure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | December 15, 2022 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $573,958 |
| NIH project number | 5R01HL162772-03 |
| Project ID | NIH-10983325 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 years old who are experiencing heart failure or related cardiac dysfunction.
✕Less likely to help
Patients with non-cardiac conditions or those under 21 years old may not benefit from this research.
What this research studies
This research investigates the role of protein phosphatase 2A (PP2A) in regulating beta-adrenergic receptors (βARs), which are crucial for heart function. It focuses on how hormones interact with these receptors and how their dysfunction can lead to heart failure. The study employs advanced techniques to explore the mechanisms of receptor desensitization and resensitization, particularly in the context of heart disease. By examining these processes, the research aims to uncover new insights into potential therapeutic targets for improving heart health.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve heart function in patients with heart failure.
How similar studies have gone: Previous research has shown promising results in understanding receptor regulation, suggesting that this approach could lead to significant advancements in cardiac care.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Prasad, Sathyamangla V — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Prasad, Sathyamangla V
Related research
Other NIH-funded projects on the same topics.
-
Susceptibility-based MRI biomarkers for multiple sclerosis
A short-term study aims to test MRI biomarkers that could help diagnose and predict MS in patients, using advanced imaging techniques.
-
Population genomics in peripartum cardiomyopathy
A gene-focused study to understand why some women develop heart failure around and after pregnancy, with an emphasis on African ancestry.
-
Broad antiviral therapy by targeting a key enzyme in nucleotide synthesis
A plan to block a human enzyme that many viruses need, with the aim of creating a broad-spectrum antiviral treatment for infections like SARS-CoV-2, influenza, and HSV-1.
-
Cellular-level Vascular Oculomics for Monitoring Systemic Vascular Health
A multi-site project using eye imaging and AI to monitor blood vessel health in people, with devices and software developed across four clinical sites.
-
Cellular-level Eye Signals to Track Vascular Health
A multi-site project aims to create and test portable imaging devices and AI tools that can monitor blood vessel health through the eye.
-
Outcomes in cirrhosis from different causes and the role of HIV and simvastatin
This study looks at how cirrhosis from alcohol, HIV, and other causes affects patients and whether simvastatin can influence outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.